A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 13, 2024

Primary Completion Date

July 11, 2025

Study Completion Date

July 11, 2025

Conditions

Migraine

Interventions

DRUG

Ubrogepant

Tablet

DRUG

Lu AG09222

Solution for injection/infusion

DRUG

Placebo

Solution for injection/infusion

Trial Locations (4)

NeuroTrials Research, Atlanta

Clinical Neuroscience Solutions, Orlando

Elevate Clinical Research, Seabrook

Future Search Trials, Austin

All Listed Sponsors

lead

H. Lundbeck A/S

INDUSTRY

NCT06578585 - A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine | Biotech Hunter | Biotech Hunter